Aurinia Pharmaceuticals Stock Forecast for 2023 - 2025 - 2030
Updated on 05/01/2024
Aurinia Pharmaceuticals Stock Forecast and Price Target
The average target price set lately by six experts for Aurinia Pharmaceuticals to reach by the end of the year is $10.00, which would imply a potential upside of approximately 96.46 percent from the previous closing price if it were to be achieved. This prediction is based on a high estimate of $15.00 and a low estimate of $8.00. Even if you're not interested in AUPH stock, you may be interested in its competitors.
96.46% Upside
Aurinia Pharmaceuticals Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Aurinia Pharmaceuticals's Price has grown, increasing from $0.00 to $0.00 – a growth of 100.00%. The next year looks promising for Aurinia Pharmaceuticals, with analysts predicting Fair Value of $5.41 – an increase of 100.00%. Over the next seven years, experts anticipate that Aurinia Pharmaceuticals's Fair Value will grow at a rate of 100.00%.
Aurinia Pharmaceuticals Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Aurinia Pharmaceuticals's Revenue has grown, increasing from $50.12M to $175.51M – a growth of 250.18%. The next year looks promising for Aurinia Pharmaceuticals, with analysts predicting Revenue of $214.58M – an increase of 22.26%. Over the next seven years, experts anticipate that Aurinia Pharmaceuticals's Revenue will grow at a rate of 208.45%.
.jpg)
Aurinia Pharmaceuticals EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Aurinia Pharmaceuticals's EBITDA has decreased from $-102.92M to $-74.14M – a 27.96% drop. For the following year, the 2 analysts predict that Aurinia Pharmaceuticals's EBITDA will drop by 60.41%, reaching $-29.35M. In 2030, the professionals' prediction is that AUPH's EBITDA will decrease by 253.85%, reaching $114.07M.
Aurinia Pharmaceuticals EBIT Forecast for 2023 - 2025 - 2030
Aurinia Pharmaceuticals's EBIT has decreased by 17.74% In the last three years, from $-104.29M to $-85.79M. In the following year, the 5 analysts surveyed believe that Aurinia Pharmaceuticals's EBIT will decrease by 43.04%, reaching $-48.87M. According to professionals, by 2030, Aurinia Pharmaceuticals's EBIT will have decreased by 396.36%, falling down to $254.25M.
Aurinia Pharmaceuticals EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Aurinia Pharmaceuticals's EPS has grown, increasing from $-0.87 to $0.00 – a growth of 100.00%. The next year looks promising for Aurinia Pharmaceuticals, with analysts predicting EPS of $-0.32 – an increase of 100.00%. Over the next seven years, experts anticipate that Aurinia Pharmaceuticals's EPS will grow at a rate of 100.00%.
Site Navigation
.jpg)